How has the new crown treatment progressed in the past two years?

Event : On February 11, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special drug approval procedures, and approved Pfizer's new coronavirus treatment drug naimatevir tablets/ritona with conditions.

Boosted by the news that Pfizer's new crown oral drug was approved with conditions, the concept of new crown drug broke out yesterday, and the popularity of domestic new crown drugs increased

Global Inventory of Treatment Methods for New Coronary Pneumonia

The current mainstream treatments for mild to moderate COVID-19 include vaccines, neutralizing antibodies, small molecule drugs, and traditional Chinese medicine

Breakthroughs in the field of global new crown vaccines are emerging one after another

Figure 1: Several major new crown vaccines that have been marketed around the world

Data source: Southwest Securities

Figure 2: New crown vaccines with the fastest progress in China (marketed, under development)

Data source: Southwest Securities

There are 6 types of COVID-19 neutralizing antibody therapies on the market globally

There are 4 new crown small molecule drugs on the market in the world, all of which are foreign companies

Figure 3: The world's fastest-growing new crown treatment drugs

Data source: Southwest Securities

Figure 4: The world's fastest-growing (marketed, late-clinical) neutralizing antibodies for the treatment of COVID-19

Data source: Southwest Securities

In addition, among the monoclonal antibody drugs, tocilizumab of Japan's Noshiogi Pharmaceutical Co.

Key Differences Between Neutralizing Antibodies and Small Molecule Drugs

Since 2021, the global COVID-19 pandemic situation has begun to come to an end.

The difference between neutralizing antibodies and small molecule drugs is also obvious in the way of administration

In terms of price, from the perspective of overseas data, the cost of neutralizing antibody treatment is higher.

At present, the domestic treatment unit price of the two domestic drugs has not been announced.

The domestic approval of Pfizer's Paxlovid has led to the outbreak of the domestic new crown drug concept.